Article Menu
Need Help?
No Article Versions Notes Found
Cite
Wong, W.W.L.; Zargar, M.; Berry, S.R.; Ko, Y.J.; Riesco-MartÃnez, M.; Chan, K.K.W. Cost-Effectiveness Analysis of Selective First-Line Use of Biologics for Unresectable RAS Wild-Type Left-Sided Metastatic Colorectal Cancer. Curr. Oncol. 2019, 26, 597-609. https://doi.org/10.3747/co.26.4843
Wong WWL, Zargar M, Berry SR, Ko YJ, Riesco-MartÃnez M, Chan KKW. Cost-Effectiveness Analysis of Selective First-Line Use of Biologics for Unresectable RAS Wild-Type Left-Sided Metastatic Colorectal Cancer. Current Oncology. 2019; 26(5):597-609. https://doi.org/10.3747/co.26.4843
Chicago/Turabian StyleWong, W.W.L., M. Zargar, S.R. Berry, Y.J. Ko, M. Riesco-MartÃnez, and K.K.W. Chan. 2019. "Cost-Effectiveness Analysis of Selective First-Line Use of Biologics for Unresectable RAS Wild-Type Left-Sided Metastatic Colorectal Cancer" Current Oncology 26, no. 5: 597-609. https://doi.org/10.3747/co.26.4843
APA StyleWong, W. W. L., Zargar, M., Berry, S. R., Ko, Y. J., Riesco-MartÃnez, M., & Chan, K. K. W. (2019). Cost-Effectiveness Analysis of Selective First-Line Use of Biologics for Unresectable RAS Wild-Type Left-Sided Metastatic Colorectal Cancer. Current Oncology, 26(5), 597-609. https://doi.org/10.3747/co.26.4843
